Theralink Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THER research report →
Price Chart
About the company
Theralink Technologies, Inc. , headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products.
- CEO
- Michael I. Ruxin
- IPO
- 2010
- Employees
- 16
- HQ
- Golden, CO, US
Get TickerSpark's AI analysis on THER
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $615.15K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 1.01
- P/B
- -0.00
- EV/EBITDA
- -2.22
- Div Yield
- 0.00%
- Gross Margin
- 79.20%
- Op Margin
- -1479.80%
- Net Margin
- -5093.56%
- ROE
- 147.47%
- ROIC
- 48.92%
Latest fiscal year · YoY change
- Revenue
- $606.80K+6.8%
- Gross Profit
- $480.56K+40.1%
- Op Income
- $-8,979,367
- Net Income
- $-30,907,505-142.4%
- EPS
- $-0.50-127.3%
- OCF Growth
- -7.1%
- FCF Growth
- -7.6%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 8.99
- RSI (14)
- 52
- Avg Volume
- 19.33K
No earnings-call transcripts are available for THER yet.
- Free Float
- 100.0%
- Shares Outstanding
- 6.15B
- Float Shares
- 6.15B
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 29, 22 | Busch Jeffrey | other | 88,424,286 |
| Apr 22, 23 | Busch Jeffrey | other | 44,314,286 |
| Nov 29, 22 | Busch Jeffrey | other | 15,714,286 |
| Nov 29, 22 | Busch Jeffrey | other | 0 |
| Apr 22, 23 | Busch Jeffrey | other | 0 |
| Nov 29, 22 | Holley Danica | other | 17,029,905 |
| Nov 29, 22 | Holley Danica | other | 2,100,840 |
| Nov 29, 22 | Holley Danica | other | 0 |
| Nov 29, 22 | Holley Danica | other | 0 |
| Nov 29, 22 | Schwartz Matthew Wilson | other | 34,571,111 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our THER coverage
Recent articles, reports, and earnings notes.
No research on THER yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate THER report →Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
globenewswire.com · Dec 18
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
globenewswire.com · Nov 13
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board
globenewswire.com · Nov 3
Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
globenewswire.com · Oct 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.